Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell survival and confer resistance to anti-leukemic drugs. There is evidence that BM microenvironment contains hypoxic areas that confer survival advantage to hematopoietic ce...
Main Authors: | Benito, Juliana, Shi, Yuexi, Szymanska, Barbara, Carol, Hernan, Boehm, Ingrid, Lu, Hongbo, Konoplev, Sergej, Fang, Wendy, Zweidler-McKay, Patrick A., Campana, Dario, Borthakur, Gautam, Bueso-Ramos, Carlos, Shpall, Elizabeth, Thomas, Deborah A., Jordan, Craig T., Kantarjian, Hagop, Wilson, William R., Lock, Richard, Andreeff, Michael, Konopleva, Marina |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154919/ |
Similar Items
-
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
by: Foehrenbacher, Annika, et al.
Published: (2013) -
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
by: Guise, Christopher P., et al.
Published: (2014) -
CH-01 is a Hypoxia-Activated Prodrug That Sensitizes
Cells to Hypoxia/Reoxygenation Through Inhibition of Chk1 and Aurora
A
by: Cazares-Körner, Cindy, et al.
Published: (2013) -
Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
by: Stokes, Ashley M., et al.
Published: (2016) -
Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
by: Foehrenbacher, Annika, et al.
Published: (2013)